Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1966 1
1967 4
1968 4
1969 9
1970 1
1971 3
1972 3
1973 8
1974 9
1975 16
1976 22
1977 19
1978 16
1979 23
1980 23
1981 27
1982 44
1983 33
1984 40
1985 58
1986 43
1987 57
1988 56
1989 65
1990 86
1991 74
1992 75
1993 68
1994 92
1995 94
1996 110
1997 111
1998 113
1999 150
2000 136
2001 139
2002 146
2003 168
2004 198
2005 194
2006 220
2007 240
2008 258
2009 290
2010 306
2011 322
2012 346
2013 385
2014 370
2015 375
2016 390
2017 364
2018 421
2019 406
2020 417
2021 392
2022 360
2023 332
2024 145

Text availability

Article attribute

Article type

Publication date

Search Results

7,936 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Localized Malignant Brain Neoplasm"
Page 1
Management of glioblastoma: State of the art and future directions.
Tan AC, Ashley DM, López GY, Malinzak M, Friedman HS, Khasraw M. Tan AC, et al. CA Cancer J Clin. 2020 Jul;70(4):299-312. doi: 10.3322/caac.21613. Epub 2020 Jun 1. CA Cancer J Clin. 2020. PMID: 32478924 Free article. Review.
Glioblastoma is the most common malignant primary brain tumor. Overall, the prognosis for patients with this disease is poor, with a median survival of <2 years. ...Innovative clinical trial designs with biomarker-enrichment strategies are needed to …
Glioblastoma is the most common malignant primary brain tumor. Overall, the prognosis for patients with this disease is poor, …
Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline.
Vogelbaum MA, Brown PD, Messersmith H, Brastianos PK, Burri S, Cahill D, Dunn IF, Gaspar LE, Gatson NTN, Gondi V, Jordan JT, Lassman AB, Maues J, Mohile N, Redjal N, Stevens G, Sulman E, van den Bent M, Wallace HJ, Weinberg JS, Zadeh G, Schiff D. Vogelbaum MA, et al. J Clin Oncol. 2022 Feb 10;40(5):492-516. doi: 10.1200/JCO.21.02314. Epub 2021 Dec 21. J Clin Oncol. 2022. PMID: 34932393
Patients with symptomatic brain metastases should receive local therapy regardless of the systemic therapy used. For patients with asymptomatic brain metastases, local therapy should not be deferred unless deferral is specifically recommended in this g …
Patients with symptomatic brain metastases should receive local therapy regardless of the systemic therapy used. For patients …
How did lomustine become standard of care in recurrent glioblastoma?
Weller M, Le Rhun E. Weller M, et al. Cancer Treat Rev. 2020 Jul;87:102029. doi: 10.1016/j.ctrv.2020.102029. Epub 2020 May 4. Cancer Treat Rev. 2020. PMID: 32408220 Free article. Review.
Glioblastomas are the most common malignant primary intrinsic brain tumors. Their incidence increases with age, and males are more often affected. ...In clinical trials, lomustine alone has been increasingly used as a control arm, assigning this drug a standa …
Glioblastomas are the most common malignant primary intrinsic brain tumors. Their incidence increases with age, and males are …
Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC.3): a multicentre, randomised, controlled, phase 3 trial.
Brown PD, Ballman KV, Cerhan JH, Anderson SK, Carrero XW, Whitton AC, Greenspoon J, Parney IF, Laack NNI, Ashman JB, Bahary JP, Hadjipanayis CG, Urbanic JJ, Barker FG 2nd, Farace E, Khuntia D, Giannini C, Buckner JC, Galanis E, Roberge D. Brown PD, et al. Lancet Oncol. 2017 Aug;18(8):1049-1060. doi: 10.1016/S1470-2045(17)30441-2. Epub 2017 Jul 4. Lancet Oncol. 2017. PMID: 28687377 Free PMC article. Clinical Trial.
BACKGROUND: Whole brain radiotherapy (WBRT) is the standard of care to improve intracranial control following resection of brain metastasis. ...We aimed to establish the effect of SRS on survival and cognitive outcomes compared with WBRT in patients with resected …
BACKGROUND: Whole brain radiotherapy (WBRT) is the standard of care to improve intracranial control following resection of brain …
Photodynamic Therapy of Malignant Gliomas.
Kaneko S, Fujimoto S, Yamaguchi H, Yamauchi T, Yoshimoto T, Tokuda K. Kaneko S, et al. Prog Neurol Surg. 2018;32:1-13. doi: 10.1159/000469675. Epub 2018 Jul 10. Prog Neurol Surg. 2018. PMID: 29990969 Review.
Recently, the clinical applications of photodynamic therapy (PDT) in the management of malignant brain tumors have attracted significant attention. ...Overall, PDT may be considered to be a safe and effective adjuvant therapeutic option for patients with newl …
Recently, the clinical applications of photodynamic therapy (PDT) in the management of malignant brain tumors have attr …
Integrated treatment of brain metastases.
Rosenfelder N, Brada M. Rosenfelder N, et al. Curr Opin Oncol. 2019 Nov;31(6):501-507. doi: 10.1097/CCO.0000000000000573. Curr Opin Oncol. 2019. PMID: 31436564 Review.
PURPOSE OF REVIEW: Optimal treatment of brain metastases has been limited to local treatment with few systemic options. ...We review the existing evidence for individual treatments and new evidence for the integration of systemic and combination of local trea …
PURPOSE OF REVIEW: Optimal treatment of brain metastases has been limited to local treatment with few systemic options. ...We …
Immune-checkpoint inhibitors for glioblastoma: what have we learned?
Omuro A. Omuro A. Arq Neuropsiquiatr. 2022 May;80(5 Suppl 1):266-269. doi: 10.1590/0004-282X-ANP-2022-S129. Arq Neuropsiquiatr. 2022. PMID: 35976319 Free PMC article. Review.
BACKGROUND: Glioblastoma, the most common malignant primary brain tumor, remains a lethal disease with few therapeutic options. ...Phase 1 studies of nivolumab with and without ipilimumab, as well as pembrolizumab, showed no new safety concerns in brain tumor …
BACKGROUND: Glioblastoma, the most common malignant primary brain tumor, remains a lethal disease with few therapeutic options …
Microglia-Centered Combinatorial Strategies Against Glioblastoma.
Martins TA, Schmassmann P, Shekarian T, Boulay JL, Ritz MF, Zanganeh S, Vom Berg J, Hutter G. Martins TA, et al. Front Immunol. 2020 Sep 29;11:571951. doi: 10.3389/fimmu.2020.571951. eCollection 2020. Front Immunol. 2020. PMID: 33117364 Free PMC article. Review.
We provide a comprehensive overview of current immunotherapeutic clinical trials and approaches for the treatment of GBM, which in general, underestimate the counteracting contribution of immunosuppressive MG as a main factor for treatment failure. ...This ultimately conve …
We provide a comprehensive overview of current immunotherapeutic clinical trials and approaches for the treatment of GBM, which in ge …
Current Treatment of Melanoma Brain Metastasis.
Rishi A, Yu HM. Rishi A, et al. Curr Treat Options Oncol. 2020 Apr 30;21(6):45. doi: 10.1007/s11864-020-00733-z. Curr Treat Options Oncol. 2020. PMID: 32350685 Review.
With greater understanding of underlying biology and development of effective BRAF-targeted therapy and immunotherapy, along with remarkable advances in local treatment such as stereotactic radiosurgery, melanoma brain metastasis (MBM) is witnessing continually impr …
With greater understanding of underlying biology and development of effective BRAF-targeted therapy and immunotherapy, along with remarkable …
Combination immunotherapy strategies for glioblastoma.
Chan HY, Choi J, Jackson C, Lim M. Chan HY, et al. J Neurooncol. 2021 Feb;151(3):375-391. doi: 10.1007/s11060-020-03481-0. Epub 2021 Feb 21. J Neurooncol. 2021. PMID: 33611705 Review.
Recent preclinical and clinical studies have explored combining ICB with several other therapies including additional ICB against alternative checkpoint molecules, activation of costimulatory checkpoint molecules such as 4-1BB, radiation-induced tumor cell lysis and immuno …
Recent preclinical and clinical studies have explored combining ICB with several other therapies including additional ICB against alt …
7,936 results